Amgen reported a strong first quarter marked by robust 24% growth across its key product drivers, propelling a raise in full-year guidance and accelerating its expansive obesity and AI-driven clinical pipeline.
Amgen has reinforced its dominance in the thyroid eye disease market following positive Phase 3 results for a subcutaneous formulation of TEPEZZA. Delivering efficacy on par with its intravenous predecessor, this development secures a multi-billion-dollar franchise while effectively neutralizing emerging competitive threats.
Amgen capped off 2025 with strong operational execution, delivering double-digit revenue and earnings per share growth across a diverse portfolio. As the company transitions into a critical launch phase for its obesity pipeline, management outlined robust financial expectations that balance near-term competitive pressures with aggressive investments in a potential blockbuster cardiometabolic franchise.